GermanyGermany

Wilex finds US commercialisation partner for Rencarex

03.05.2011

Munich/San Diego – German Wilex has sold the exclusive US marketing rights for RENCAREX® (girentuximab), its Phase III monoclonal antibody for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC) to Prometheus Laboratories Inc. Under the terms of the agreement, Wilex will receive $19.0 million upfront, development fees, plus milestone payments and royalties on U.S. net sales of the chimeric monoclonal antibody that targets the CA IX-antigen, which is overexpressed on 95% of ccRCC and various other solid tumours. Additionally, Wilex has options for commercialisation outside the United States to one of Prometheus' marketed products or additional cash payments of up to $20 million. With the deal, the US company, which has a track record of commercialisation of oncology products, strengthens its oncology pipeline. girentuximab is currently being tested in a Phase III trial versus placebo in the adjuvant setting in 864 patients with non-metastatic clear cell renal cell cancer at high risk of recurrence after nephrectomy. WILEX expects the results from the interim analysis for efficacy of girentuximab in the second half of 2011, which could form the basis for the European MAA.

GermanyGermany

11.11.2010

Berlin – Germany has launched a research programme aimed at establishing a bio-based economy by 2030. "Our goal is to support the shift in industrial production from oil-based towards bio-based CO2-neutral, sustainable, and...

GermanyGermany

04.11.2010

Mannheim – German researchers have patented a non-invasive sensor chip that can permanently monitor kidney and liver function. “Our chip can be used for toxicity testing of preclinical drugs in animals. Next year, we are going to...

GermanyGermany

04.11.2010

Planegg-Martinsried – Drug discovery specialist 4SC AG’s oral immunosuppressant Vidofludimus (SC12267, 4SC-101) has provided promisingdata in an exploratory open-label Phase IIa study on 34 patients with inflammatory bowel...

GermanyGermany

04.11.2010

These days, front-page biotech-related headlines are as rare as reports of a sector-driven rally. Supranational threats and crises, on the other hand, are practically everyday events. For instance, it would have been...

GermanyGermany

04.11.2010

Steven M. Zeman, Ph.D., Dr. Franz-Josef Zimmer, European Patent Attorneys at Grünecker Patent- und Rechtsanwälte, Munich

GermanyGermany

03.11.2010

Monheim /West Palm Beach – Bayer CropScience and SentiSearch, Inc. have entered into a two-year research agreement to cooperate in the identification of new molecules targeting odourant receptors in insects. The aim of the...

GermanyGermany

03.11.2010

Dr. Christel Fenge joined Sartorius Stedim Biotech (Göttingen, Aubagne) as VP Marketing for Fermentation Technologies in mid-October. A former General Manager at Recipharm Biologics, Fenge will manage Sartorius’ global business...

GermanyGermany

03.11.2010

A Hanover – Belgian target discovery specialist Galapagos Genomics NV has bagged Europe’s biggest prize for a biotech company. On the evening prior to the opening of the Biotechnica congress-fair in Hanover (October 5th-7th),...

GermanyGermany

19.10.2010

Luxembourg – EU environment ministers believe that the EuropeanCommission’s proposal to allow national GMO cultivation bans is incompatible with rules of the World Trade Organisation (WTO) and undermines the EU’s internal market....

Displaying results 71 to 80 out of 454

< Previous 71-80 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/7/article/wilex-finds-us-commercialisation-partner-for-rencarex.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF53.7%
  • BB BIOTECH141.00 EUR6.3%
  • ADDEX3.98 CHF4.2%

FLOP

  • WILEX2.25 EUR-24.7%
  • MOLOGEN7.38 EUR-18.8%
  • 4SC1.22 EUR-15.9%

TOP

  • SANTHERA98.35 CHF4121.0%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR179.3%

FLOP

  • CYTOS0.25 CHF-93.6%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014


Current issue

All issues

Product of the week

Products